Report Highlights

Sports Medicine in the U.S.: Market Overview

The U.S. sports medicine market was valued at USD 9.8 billion in 2024 and covers arthroscopy systems, orthobiologics, soft tissue fixation implants, bracing, and rehabilitation devices. Private manufacturers have led product development, with Arthrex, Smith+Nephew, and Stryker driving most arthroscopic and fixation innovation through FDA-cleared product families. Hospitals, ambulatory surgical centers, and physician practices purchase these products, but their decisions follow federal payment schedules.

Policy has shaped the market's current form most decisively through care-setting economics. The Centers for Medicare and Medicaid Services (CMS) Physician Fee Schedule, the Hospital Outpatient Prospective Payment System, and the Ambulatory Surgical Center Covered Procedures List have moved arthroscopic knee and shoulder procedures into lower-cost settings. State legislatures added demand through the Washington Lystedt Law (RCW 28A.600.190, enacted 2009), a concussion statute now mirrored in all 50 states that requires medical clearance before a youth athlete returns to play.

Policy-Driven Growth in U.S. Sports Medicine

Three policy mechanisms drive demand. First, CMS payment rules: the Medicare Physician Fee Schedule conversion factor of USD 32.35 for 2025 and CMS additions to the ASC Covered Procedures List make outpatient arthroscopy economically attractive, increasing unit volume for single-use implants and arthroscopy towers. Second, state concussion statutes modeled on the Lystedt Law require physician evaluation and documented clearance, increasing diagnostic imaging, rehabilitation services, and bracing volume.

Third, the Medical Device User Fee Amendments of 2022 (MDUFA V), enacted within the FDA User Fee Reauthorization Act of 2022 and running through fiscal 2027, fund FDA review staff and set 510(k) and PMA performance goals. Faster clearance allows manufacturers such as Stryker and Zimmer Biomet to launch new fixation and navigation platforms within a single product cycle. User-fee-funded review capacity compresses time-to-market, converting pipeline into revenue and expanding the installed base available to ASCs and hospitals.

Regulatory Barriers and Compliance Costs

FDA's Quality Management System Regulation, which amends 21 CFR Part 820 and incorporates ISO 13485:2016 by reference, takes effect February 2, 2026 and requires manufacturers to rebuild design-control and supplier-audit records. Standard 510(k) user fees exceeded USD 20,000 in fiscal 2025, and implant manufacturers seeking Premarket Approval face multi-year reviews administered by FDA's Center for Devices and Radiological Health. Smaller orthobiologic and bracing entrants absorb the heaviest compliance burden relative to revenue.

Financial relationship rules add a second layer. The federal Anti-Kickback Statute (42 U.S.C. 1320a-7b(b)) constrains consulting and physician-owned distribution arrangements common in sports medicine. The Physician Payment Sunshine Act, enacted under Section 6002 of the Affordable Care Act and administered by CMS through Open Payments, requires public reporting of payments of USD 10 or more to physicians. The EPA's ethylene oxide sterilizer standard under 40 CFR Part 63 Subpart O, tightened in 2024, raises costs for contract sterilizers serving implant manufacturers.

Policy-Created Opportunities in the U.S.

The CMS expansion of the ASC Covered Procedures List creates demand for ASC-ready arthroscopy towers, single-use shavers, and pre-packed knee and shoulder implant kits. Surgery Partners and United Surgical Partners International operate ASC networks that prioritize standardized, low-cost implant sets. Vendors offering these kits capture volume that hospital value analysis committees previously controlled.

Concussion policy generates diagnostic demand. FDA-cleared blood biomarker tests for mild traumatic brain injury, including Abbott's i-STAT TBI whole blood assay, give sideline and emergency clinicians an objective triage tool aligned with state-mandated evaluation protocols. Manufacturers securing clearance for sideline-deployable tests and integrating results into return-to-play documentation access a regulation-driven purchasing channel across youth, collegiate, and professional sports.

Market at a Glance

Leading Market Participants

• Arthrex
• Smith+Nephew
• Stryker
• Zimmer Biomet
• DePuy Synthes
• CONMED
• Bioventus
• Orthofix Medical
• MiMedx
• Ossur

Regulatory and Policy Environment

The centerpiece of the framework is the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), administered by FDA's Center for Devices and Radiological Health, with MDUFA V performance goals running through September 30, 2027. Medicare coverage operates under Title XVIII of the Social Security Act, implemented by CMS through annual payment rules. Key compliance requirements include the QMSR effective February 2, 2026, Unique Device Identification labeling under 21 CFR Part 801 Subpart B, Open Payments reporting by March 31 each year, and state concussion statutes in all 50 states.

Upcoming changes include MDUFA VI negotiations, which must conclude before reauthorization for fiscal 2028, and the EU legacy device deadlines extended by Regulation (EU) 2023/607 to December 31, 2027 for class III and implantable devices. Compared with peers, the U.S. grants faster 510(k) market entry than the European Union's Medical Device Regulation (EU) 2017/745 with notified-body review. Canada's Medical Devices Regulations (SOR/98-282) require Health Canada device licences for class III and IV devices, while provincial formularies lengthen adoption. U.S. advantage lies in reimbursement certainty through CMS.

Long-Term Policy Outlook for U.S. Sports Medicine

By 2032, CMS is expected to broaden the ASC Covered Procedures List further and to apply site-neutral payment policies to selected outpatient services, a reform Congress has debated in successive appropriations packages. Physician payment reform will determine whether bundled rates for arthroscopy and fixation procedures converge toward ASC economics. That shift transfers purchasing leverage from hospital systems to ASC operators and to the device makers supplying them.

MDUFA VI, covering fiscal 2028 through 2032, will set FDA review staffing and determine how quickly AI-enabled surgical navigation and imaging devices reach market. FDA's final guidance on predetermined change control plans for AI-enabled device software will govern how vendors update algorithms after clearance. By 2032, companies combining QMSR-compliant quality systems, Open Payments transparency, and ASC-ready product lines will hold the policy-advantaged position in the U.S. market.